EUVIMEDEUVIMED entdecken
Crossref

A dual-targeted trinity of antibody–peptide–drug delivery consortium to combat HER2+ tumor

Yuna Shang, Jiayu Wang, Yinyin Feng, Zhengyu Liu, Jiayi Lu, Sijia Deng, Li Li, Hongxu Zhang, Liantao Li, Zhongyan Wang iD, Zhimou Yang iD

Chemical Communications · 2024

DOI: 10.1039/d4cc05115g ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Communications, 2024. Verfasst von Yuna Shang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Interdisciplinary Studies on Intelligent Molecules, Tianjin Key Laboratory of Structure and Performance for Functional Molecules, College …. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Peptides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Jiangsu Provincial Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report for the first time that an anticancer drug–peptide conjugate containing γEγE in its side chain and RGD motif exhibits high affinity for Herceptin and facilitates self-assembly to form antibody–peptide–drug nanofibers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesPeptidesHumansDrug Delivery SystemsAnimalsCell Line, TumorDrug CarriersAntineoplastic AgentsBreast NeoplasmsNanofibersMiceAntibodies

Substanzen

Erb-b2 Receptor Tyrosine KinasesPeptidesDrug CarriersAntineoplastic AgentsAntibodiesERBB2 protein, human

Autor:innen und Institutionen

  • Academy of Interdisciplinary Studies on Intelligent Molecules, Tianjin Key Laboratory of Structure and Performance for Functional Molecules, College of Chemistry, Tianjin Normal University, Tianjin 300387, P. R. China.
  • Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P. R. China…
  • State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Tianjin Institut…
  • Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325035, Zhejiang, P. R. China. yangzm@nankai.edu.cn.

ORCID-Profile: Zhongyan Wang, Zhimou Yang

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Jiangsu Provincial Department of Science and Technology

Zitieren

APA

Shang, Y., Wang, J., Feng, Y., Liu, Z., Lu, J., Deng, S., Li, L., Zhang, H., Li, L., Wang, Z., & Yang, Z. (2024). A dual-targeted trinity of antibody–peptide–drug delivery consortium to combat HER2+ tumor. Chemical Communications. https://doi.org/10.1039/d4cc05115g

Vancouver

Shang Y, Wang J, Feng Y, Liu Z, Lu J, Deng S, et al. A dual-targeted trinity of antibody–peptide–drug delivery consortium to combat HER2+ tumor. Chemical Communications. 2024. doi:10.1039/d4cc05115g

BibTeX
@article{Shang2024,
  author = {Shang, Yuna and Wang, Jiayu and Feng, Yinyin and Liu, Zhengyu and Lu, Jiayi and Deng, Sijia and Li, Li and Zhang, Hongxu and Li, Liantao and Wang, Zhongyan and Yang, Zhimou},
  title = {A dual-targeted trinity of antibody–peptide–drug delivery consortium to combat HER2+ tumor},
  journal = {Chemical Communications},
  year = {2024},
  doi = {10.1039/d4cc05115g}
}
Kostenlos starten →